Phase I trial of sequential low-dose 5-aza-2'-deoxycytidine plus high-dose intravenous bolus interleukin-2 in patients with melanoma or renal cell carcinoma.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples